ACTRN12605000510640
Recruiting
Phase 1
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancer
peter maccallum Cancer Centre0 sites70 target enrollmentSeptember 26, 2005
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- peter maccallum Cancer Centre
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Resected SCC oral cavity, oropharynx, hypopharynx or larynx; risk factors for recurrence; no macroscopic residual disease, no prior radiotehrapy for head and neck cancer, no prior chemotherapy.
Exclusion Criteria
- •No exclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
Completed
Phase 2
A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000003274ational Hospital Organization15
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
Completed
Phase 2
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19